Definition and classification of cancer cachexia: an international consensus.

To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. The agreed diagnostic criterion for cachexia was weight loss greater than 5%, or weight loss greater than 2% in individuals already showing depletion according to current bodyweight and height (body-mass index [BMI] <20 kg/m(2)) or skeletal muscle mass (sarcopenia). An agreement was made that the cachexia syndrome can develop progressively through various stages--precachexia to cachexia to refractory cachexia. Severity can be classified according to degree of depletion of energy stores and body protein (BMI) in combination with degree of ongoing weight loss. Assessment for classification and clinical management should include the following domains: anorexia or reduced food intake, catabolic drive, muscle mass and strength, functional and psychosocial impairment. Consensus exists on a framework for the definition and classification of cancer cachexia. After validation, this should aid clinical trial design, development of practice guidelines, and, eventually, routine clinical management.

[1]  A. Jatoi Weight loss in patients with advanced cancer: effects, causes, and potential management , 2008, Current opinion in supportive and palliative care.

[2]  M. Bossola,et al.  Is malnutrition still a risk factor of postoperative complications in gastric cancer surgery? , 2008, Clinical nutrition.

[3]  F. Strasser Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue , 2008, Current opinion in clinical nutrition and metabolic care.

[4]  Mellar P. Davis,et al.  Systematic review of the treatment of cancer-associated anorexia and weight loss. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Fainsinger,et al.  Applying the Delphi process to palliative care tool development: lessons learned , 2008, Supportive Care in Cancer.

[6]  R. Ch.,et al.  NUTRITION IN GERIATRICS. , 1963 .

[7]  K. Fearon Cancer cachexia: developing multimodal therapy for a multidimensional problem. , 2008, European journal of cancer.

[8]  A. Fairchild,et al.  Is pain intensity a predictor of the complexity of cancer pain management? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Robert Ross,et al.  Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability , 2002, Journal of the American Geriatrics Society.

[10]  J. Corner,et al.  The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. , 2006, Journal of pain and symptom management.

[11]  I. Bosaeus Nutritional support in multimodal therapy for cancer cachexia , 2008, Supportive Care in Cancer.

[12]  F. López‐Soriano,et al.  Mechanisms to explain wasting of muscle and fat in cancer cachexia , 2007, Current opinion in supportive and palliative care.

[13]  Dagny Faksvåg Haugen,et al.  Symptom assessment in palliative care: a need for international collaboration. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Lisa Martin,et al.  Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer , 2009, Clinical Cancer Research.

[15]  H. Friess,et al.  Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer , 2008, Journal of Gastrointestinal Surgery.

[16]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[17]  Arya M. Sharma,et al.  A proposed clinical staging system for obesity , 2009, International Journal of Obesity.

[18]  Mellar P. Davis,et al.  Components of the anorexia–cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia , 2009, Supportive Care in Cancer.

[19]  B. Jasmin,et al.  Molecular events and signalling pathways involved in skeletal muscle disuse-induced atrophy and the impact of countermeasures , 2009, Journal of cellular and molecular medicine.

[20]  J. Kitzinger,et al.  Qualitative Research: Introducing focus groups , 1995 .

[21]  L. Birdsell,et al.  The emerging role of computerized tomography in assessing cancer cachexia , 2009, Current opinion in supportive and palliative care.

[22]  R. Wolfe,et al.  Atrophy and impaired muscle protein synthesis during prolonged inactivity and stress. , 2006, The Journal of clinical endocrinology and metabolism.

[23]  M. Tschöp,et al.  CLINICAL STUDIES , 2022 .

[24]  F. López‐Soriano,et al.  The role of cytokines in cancer cachexia , 1999, Medicinal research reviews.

[25]  C. Tishelman,et al.  The use of artificial nutrition among cancer patients enrolled in palliative home care services , 2009, Palliative medicine.

[26]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[27]  F. Strasser,et al.  Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study , 2007, Palliative medicine.

[28]  L. Mccargar,et al.  Nutrition impact symptoms: Key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment , 2009, Head & neck.

[29]  F. Strasser Appraisal of current and experimental approaches to the treatment of cachexia , 2007, Current opinion in supportive and palliative care.

[30]  K. Fearon,et al.  Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids , 2004, British Journal of Cancer.

[31]  L. Mccargar,et al.  Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment , 2009, Clinical Cancer Research.

[32]  Reader,et al.  An exploration of the experience of cancer cachexia: what patients and their families want from healthcare professionals , 2010 .

[33]  L. Mariani,et al.  Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. , 2009, JPEN. Journal of parenteral and enteral nutrition.

[34]  S. Heymsfield,et al.  Epidemiology of sarcopenia among the elderly in New Mexico. , 1998, American journal of epidemiology.

[35]  Tony Reiman,et al.  Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity , 2007, Clinical Cancer Research.

[36]  Y. Kusui Loss of Appetite , 1963, Science.

[37]  K. Fox,et al.  Estimation of Cachexia among Cancer Patients Based on Four Definitions , 2009, Journal of oncology.

[38]  G. Biolo,et al.  Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". , 2010, Clinical nutrition.

[39]  H. Andreyev,et al.  The views and practice of oncologists towards nutritional support in patients receiving chemotherapy , 2006, British Journal of Cancer.

[40]  Stephen J. Clarke,et al.  Nutritional Assessment in Cancer: Comparing the Mini-Nutritional Assessment (MNA) With the Scored Patient-Generated Subjective Global Assessment (PGSGA) , 2005, Nutrition and cancer.

[41]  A. Hildreth,et al.  A questionnaire study of the approach to the anorexia–cachexia syndrome in patients with cancer by staff in a district general hospital , 2009, Supportive Care in Cancer.

[42]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[43]  Kevin D Hall,et al.  A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. , 2009, The American journal of clinical nutrition.

[44]  A. Hildreth,et al.  Quantifying the impact of standardized assessment and symptom management tools on symptoms associated with cancer-induced anorexia cachexia syndrome , 2009, Palliative medicine.

[45]  J. Ross,et al.  Cancer cachexia is associated with the IL10 -1082 gene promoter polymorphism in patients with gastroesophageal malignancy. , 2009, The American journal of clinical nutrition.

[46]  K. Fearon,et al.  Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. , 2006, The American journal of clinical nutrition.

[47]  H. Kauczor,et al.  Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia , 2009, Acta oncologica.

[48]  G. Murray,et al.  Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.